Composition(s) for Topically Treating Pain

Abstract

Pharmaceutically effective compositions and methods for topically treating pain due to swelling or inflammation of fascia, tendons, or ligaments in a patient in need of treatment, thereof. The pharmaceutically effective composition consists essentially of: 68.6-29.4 parts by weight of a pharmaceutically acceptable excipient; 40.0-50.0 parts by weight DMSO; 1.0-5.0 parts by weight of an anesthetic, wherein the anesthetic is advantageously characterized as containing only lidocaine; and 1.2-3.2 parts by weight of an anti-inflammatory in 100 parts by weight of the pharmaceutically effective composition. In one embodiment, the anesthetic is advantageously 4.0 parts by weight Lidocaine. In one embodiment, the pharmaceutically acceptable excipient is 48.0 parts by weight, DMSO is 45 parts by weight, anesthetic is advantageously 4.0 parts by weight Lidocaine, Echinaceas is 1.0 part by weight and Arnica is 1.0 part by weight, and the condition causing pain of the foot is Plantar Fasciitis.

We claim: 
     
         1 - 22 . (canceled) 
     
     
         23 . A pharmaceutically effective composition for topically treating pain due to swelling or inflammation of fascia, tendons or ligaments in a patient in need of treatment, thereof, consisting essentially of:
 In 100 parts by weight of the composition:   68.6-29.4 parts by weight of a pharmaceutically acceptable excipient;   10.0-50.0 parts by weight DMSO;   1.0-5.0 parts by weight of an anesthetic, wherein the anesthetic is characterized as containing only lidocaine; and   1.2-3.2 parts by weight of an anti-inflammatory.   
     
     
         24 . The composition of  claim 23 , wherein the pharmaceutically acceptable excipient comprises:
 0.6-1.6 parts by weight hydroxypropyl cellulous NF, resulting in a viscosity of the composition being from about 18,000 cps to about 42,000 cps at 20° C.   
     
     
         25 . The composition of  claim 23 , wherein the pharmaceutically acceptable excipient is selected from the group of excipients consisting essentially of DMSO, isopropyl alcohol, propylene glycol (PG), ethylene glycol (EG), polypropylene glycol (PPG), diethylene glycol monosubstituted ether (DGMSE), BHT, glycerin, propylene glycol, transcutol, triethanolamine, hydroxypropyl cellulose, nitrocellulose and hydroxypropyl Cellulose (NF), hydroxypropyl cellulose (HPC), and combinations thereof. 
     
     
         26 . The composition of  claim 23 , wherein the anesthetic is in the range of 3.0 to 5.0 parts by weight Lidocaine. 
     
     
         27 . The composition of  claim 23 , wherein the pharmaceutically effective composition consists essentially of 48.0 parts by weight pharmaceutically acceptable excipient, 45 parts by weight DMSO, 4.0 parts by weight anesthetic, wherein the anesthetic is characterized as containing only lidocaine, and the anti-inflammatory consists essentially of 1.0 part by weight Echinaceas and 1.0 part by weight Arnica. 
     
     
         28 . The composition of  claim 27 , wherein the pharmaceutically acceptable excipient contains 1.0 part hydroxypropyl cellulous NF, resulting in a viscosity of the composition being in the range of about 18,000 cps to about 42,000 cps at 20° C. 
     
     
         29 . The composition of  claim 23 , wherein the anti-inflammatory is selected from the group consisting of Echinacea, Arnica, and combinations thereof. 
     
     
         30 . The composition of  claim 27 , wherein the Echinacea and Arnica are each in the range 0.6 to 1.2 parts by weight.